In China, a 4-year cohort study of 13,240 participants with NAFLD found that participants who eventually developed NAFLD had significant differences in ALT levels from those who did not develop the disease [52]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.